802541-13-5

Basic information

• Product Name: 1H-Indazole-3-carboxylicacid,4,5,6,7-tetrahydro-1-methyl-7-oxo-,ethylester(9CI)
• Synonyms: 1H-Indazole-3-carboxylicacid,4,5,6,7-tetrahydro-1-methyl-7-oxo-,ethylester(9CI);1H-Indazole-3-carboxylicacid,4,5,6,7-tetrahydro-1-methyl-7-oxo-,ethylester;4,5,6,7-Tetrahydro-1-methyl-7-oxo-1H-indazole-3-carboxylicacid ethyl ester;1-Methyl-7-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid ethyl ester
• CAS NO: 802541-13-5
• Molecular Formula: C11H14N2O3
• Molecular Weight: 222.24
• Product Categories: METHYL;Indazoles
• Mol File: 802541-13-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 405.353°C at 760 mmHg
• Flash Point: 198.95°C
• Appearance: /
• Density: 1.327g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.607
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1H-Indazole-3-carboxylicacid,4,5,6,7-tetrahydro-1-methyl-7-oxo-,ethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole-3-carboxylicacid,4,5,6,7-tetrahydro-1-methyl-7-oxo-,ethylester(9CI)(802541-13-5)
• EPA Substance Registry System: 1H-Indazole-3-carboxylicacid,4,5,6,7-tetrahydro-1-methyl-7-oxo-,ethylester(9CI)(802541-13-5)

Safety Data

• Hazardous Substances Data: 802541-13-5(Hazardous Substances Data)

Usage

General Description

1H-Indazole-3-carboxylic acid, 4,5,6,7-tetrahydro-1-methyl-7-oxo-, ethylester (9CI) is a chemical compound with a complex structure containing an indazole ring and a carboxylic acid group. It also has a methyl and oxo group, as well as an ethyl ester. 1H-Indazole-3-carboxylicacid,4,5,6,7-tetrahydro-1-methyl-7-oxo-,ethylester(9CI) has potential applications in pharmaceutical research, particularly in the development of new drugs. Its specific properties and potential uses would need to be further investigated through research and testing.

InChI:InChI=1/C11H14N2O3/c1-3-16-11(15)9-7-5-4-6-8(14)10(7)13(2)12-9/h3-6H2,1-2H3

Upstream product

• 802541-12-4 ethyl (3-ethoxy-2-oxocyclohex-3-en-1-yl)-(oxo)acetate 
• 60-34-4 methylhydrazine 
• 95-92-1 oxalic acid diethyl ester 
• 23740-37-6 2-methoxycyclohex-2-en-1-one 
• 302-15-8 methylhydrazine sulfuric acid 

Downstream Products

• 802534-49-2 ethyl 8-amino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate 
• 802534-50-5 ethyl 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate 

Relevant articles and documents

Pyrazolo [4, 3 - h] aminoquin oxazolines and use thereof (by machine translation)

The invention relates to a kind of the following formula I indicated by the pyrazolo [4, 3 - h] quinazoline derivatives and their use, the compounds inhibit the cell cycle protein dependent enzyme family (CDKs) in different subtype for example CDK4/6 activity, for the prevention and treatment of cancer, metabolic immune diseases, cardiovascular disease and the provision of new means of neurological diseases. (by machine translation)

Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl] amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor

The discovery of a novel class of inhibitors of cyclin dependent kinases (CDKs) is described. Starting from compound 1, showing good potency as inhibitor of CDKs but being poorly selective against a panel of serine-threonine and tyrosine kinases, new analogues were synthesized. Enhancement in selectivity, antiproliferative activity against A2780 human ovarian carcinoma cells, and optimization of the physical properties and pharmacokinetic profile led to the identification of highly potent and orally available compounds. Compound 28 (PHA-848125), which in the preclinical xenograft A2780 human ovarian carcinoma model showed good efficacy and was well tolerated upon repeated daily treatments, was identified as a drug candidate for further development. Compound 28 is currently undergoing phase I and phase II clinical trials.

PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.